Form 4: Johnson & Johnson Executive Kathryn E. Wengel Reports Stock Transactions
SEC Form 4 Filing
Kathryn E. Wengel, EVP, Chief TO and Risk Officer of Johnson & Johnson, reports multiple transactions involving common stock and restricted/performance share units from February 13, 2025, to February 18, 2025.
Summary
- Kathryn E. Wengel, an executive at Johnson & Johnson, filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
- The reported transactions occurred between February 13, 2025, and February 18, 2025.
- These transactions include the vesting and conversion of Restricted Share Units (RSUs) and Performance Share Units (PSUs) into common stock.
- Shares were also withheld for payment of taxes upon the vesting of RSUs and PSUs.
- Wengel's direct holdings of Johnson & Johnson common stock increased due to the vesting of these units.
- She also has indirect ownership through the company's ESOP and 401k plans.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, and does not inherently convey positive or negative sentiment.
Positives
- The vesting of RSUs and PSUs indicates that performance metrics were likely met, leading to the conversion of these units into common stock.
Industry Context
Form 4 filings are a routine part of executive compensation and provide transparency into the trading activities of company insiders.
Comparison to Industry Standards
- Executive compensation packages at large pharmaceutical companies like Johnson & Johnson typically include a mix of salary, stock options, restricted stock units, and performance-based incentives.
- The vesting schedules and terms of these equity awards are generally aligned with industry best practices to incentivize long-term value creation and retention.
- Companies like Pfizer (PFE) and Merck (MRK) also utilize similar equity-based compensation structures for their executives.
Stakeholder Impact
- The transactions have a minimal direct impact on shareholders, employees, customers, suppliers, and creditors.
- The filing provides transparency to shareholders regarding executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 01/31/2025 | Date of the Plan's most recent reporting date for ESOP and 401k holdings. |
| 02/13/2023 | Date of RSU award that vests in three annual equal installments beginning on the first anniversary of the grant date. |
| 02/14/2022 | Date of RSU and PSU awards that vest three years after the date of grant. |
| 02/13/2025 | Transaction date for the vesting of 651 Restricted Share Units (RSUs). |
| 02/14/2025 | Transaction date for the vesting of 1,530 RSUs and 5,837 Performance Share Units (PSUs). |
| 02/15/2024 | Date of RSU award that vests in three annual equal installments beginning on the first anniversary of the grant date. |
| 02/15/2025 | Transaction date for the vesting of 607 Restricted Share Units (RSUs). |
| 02/18/2025 | Date of signature for the Form 4 filing. |
Keywords
Form 4, beneficial ownership, Kathryn E. Wengel, Johnson & Johnson, JNJ, restricted share units, performance share units, stock options, executive compensation, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.